Background: Colchicine is an old well-known venerable drug routinely used in gout attacks for instance. More recnetly it is regularly use in the treatment of pericarditis. It couls exert antiiflammatory effects targeting the adverse inflammation occuring incase of acute myocardial infarction, which is involved in poor outcomes or longer stay at hospital. Endpoints: * Main endpoint: AUC CRP during the initial hospital stay * Secondary endpoints: * Clinical: oucomes * Imaging: ETT, MRI * Biological: various biomarkers Method Randomized, controled, open-labbelled, comparing two parallel arms: conventionnal optimal treatment versus conventionnal optimal treatment + colchicine
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
44
University Hospital Arnaud de Villeneuve
Montpellier, France
AUC CRP
Time frame: 5 days
Drug tolerance
Clinical outcome
Time frame: 1 year
hospitalization time
Clinical outcome
Time frame: 1 year
CRP measurement
Intrahospital peak CPK (Biological outcome)
Time frame: 1 year
CPK measurement
Size IDM (pic and kinetics) (Biological outcome)
Time frame: 1 year
Troponin-hs measurement
Size IDM (pic and kinetics) (Biological outcome)
Time frame: 1 year
Creatinine level
Biological outcome
Time frame: Day of inclusion and one month after inclusion
measurement of left ventricular end-systolic volume
Remodeling ETT
Time frame: Day of inclusion and one month after inclusion
measurement of left ventricular diastolic volume
Remodeling ETT
Time frame: Day of inclusion and one month after inclusion
measurement remodeling
Remodeling ETT
Time frame: One month after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.